0001610717-24-000036.txt : 20240119
0001610717-24-000036.hdr.sgml : 20240119
20240119204459
ACCESSION NUMBER: 0001610717-24-000036
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240118
FILED AS OF DATE: 20240119
DATE AS OF CHANGE: 20240119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McCarthy Sean A.
CENTRAL INDEX KEY: 0001654058
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37587
FILM NUMBER: 24546902
MAIL ADDRESS:
STREET 1: 343 OYSTER POINT BLVD.
STREET 2: SUITE 100
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CytomX Therapeutics, Inc.
CENTRAL INDEX KEY: 0001501989
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 273521219
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650.515.3185
MAIL ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
form4.xml
X0508
4
2024-01-18
0001501989
CytomX Therapeutics, Inc.
CTMX
0001654058
McCarthy Sean A.
C/O CYTOMX THERAPEUTICS, INC.
151 OYSTER POINT BLVD., STE. 400
SOUTH SAN FRANCISCO
CA
94080
true
true
CEO
false
Common Stock
2024-01-18
4
A
0
90000
0
A
544704
D
Common Stock
93158
I
See footnote
Stock Option (Right to Buy)
1.68
2024-01-18
4
A
0
420000
0
A
2034-01-17
Common Stock
420000
420000
D
Performance Stock Units (PSUs)
2024-01-18
4
A
0
260000
0
A
Common Stock
260000
260000
D
Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2025, subject to the Reporting Person continuing as a service provider through each such date.
Includes 251,250 RSUs.
Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee.
1/48th of the shares subject to the option vest on each monthly anniversary measured from January 18, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.
/s/ Lloyd Rowland, as Attorney-in-Fact for Sean A. McCarthy
2024-01-19